In a special comment, Dr Brendan Shaw, the principal of Shawview Consulting, former CEO of MS and and assistant director-general of the IFPMA, says the PBS and Australian pharmaceutical policy have suffered some shocks in the past but nothing compares to COVID-19.
Latest Video
New Stories
-
Scorecard reveals Australia is still ignoring its deadliest and most costly cancer
November 26, 2025 - - Latest News -
Australian melanoma oncologist awarded inaugural Marie Krogh Prize for Young Women in Science
November 26, 2025 - - Latest News -
Updated asthma guidelines warn against ‘blue puffer only’ treatment as deaths remain stubbornly high
November 26, 2025 - - Latest News -
Australia has 'all the ingredients' but has to decide what kind of health system it wants
November 26, 2025 - - BioPharma -
Report calls for Type 1 diabetes screening with 25,000 unknowingly living with early disease
November 26, 2025 - - Latest News -
New report shows precision approach extends lives but many still missing out
November 25, 2025 - - Latest News -
AusBiotech appoints Anthea Stephenson to lead national industry growth program
November 25, 2025 - - Australian Biotech
